Isotretinoin‐associated intracranial hypertension: A concise report
JEADV Clinical Practice · 2024-12 · 3 (5) · 1627-1630
DOI: 10.1002/jvc2.470 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 11.06.2024. Verfasst von Kanya Rani Vashisht und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We present a case of a 24‐year‐old preobese female undergoing isotretinoin treatment for acne vulgaris, who experienced drug‐induced intracranial hypertension (DIIH). Recognizing and addressing this potentially serious adverse effect is essential to prevent severe outcomes, particularly irreversible vision impairment. When suspected, immediate discontinuation of isotretinoin, neuroradiological imaging and urgent ophthalmologic evaluation to rule out papilloedema is imperative. Formulation of alternative treatment strategies, caution while prescribing DIIH‐causing drugs in future patient treatments and proactive reporting of adverse events are integral aspects of its comprehensive management.
Zitieren
APA
Vashisht, K. R., Varma, S., & Yeganegi, M. (2024). Isotretinoin‐associated intracranial hypertension: A concise report. JEADV Clinical Practice, 3(5), 1627-1630. https://doi.org/10.1002/jvc2.470
Vancouver
Vashisht KR, Varma S, Yeganegi M. Isotretinoin‐associated intracranial hypertension: A concise report. JEADV Clinical Practice. 2024;3(5):1627-1630. doi:10.1002/jvc2.470
BibTeX
@article{Vashisht2024,
author = {Vashisht, Kanya Rani and Varma, Sachin and Yeganegi, Mahtab},
title = {Isotretinoin‐associated intracranial hypertension: A concise report},
journal = {JEADV Clinical Practice},
year = {2024},
volume = {3},
number = {5},
pages = {1627--1630},
doi = {10.1002/jvc2.470}
}
EUVIMED